Deep Medicine Acquisition Corp. Rights
DMAQR
DMAQR was delisted on the 31st of January, 2024.
30 hedge funds and large institutions have $1.34M invested in Deep Medicine Acquisition Corp. Rights in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 3 closing their positions.
132% more capital invested
Capital invested by funds: $576K → $1.34M (+$760K)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
3% more funds holding
Funds holding: 29 → 30 (+1)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
+$20.3K |
| 2 |
SOA
Sea Otter Advisors
Miami,
Florida
|
+$15.2K |
| 3 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
+$7.09K |
| 4 |
Millennium Management
New York
|
+$3.34K |
| 5 |
Walleye Capital
New York
|
+$2.92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$24.8K |
| 2 |
CAC
Cowen and Company
New York
|
-$24K |
| 3 |
CS
Clear Street
New York
|
-$23K |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$11.1K |
| 5 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$10.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BRF
26
B. Riley Financial
Los Angeles,
California
| $6.89K | -$10 | -100 | -0.2% |
|
|
27
Hudson Bay Capital Management
Stamford,
Connecticut
| $6.33K | -$24.8K | -245,300 | -84% |
|
|
HF
28
HRT Financial
New York
| $6K | – | – | – |
|
|
29
Millennium Management
New York
| $5K | +$3.34K | +33,000 | New |
|
|
BCM
30
Bluefin Capital Management
New York
| $2.1K | -$1.52K | -14,975 | Closed |
|
|
AA
31
Ancora Advisors
Cleveland,
Ohio
| $755 | – | – | – |
|
|
CS
32
Clear Street
New York
| – | -$23K | -377,501 | Closed |
|
DMAQR Hedge Fund Activity: Q1 2023 in Review
30 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Deep Medicine Acquisition Corp. Rights (DMAQR) for Q1 2023, worth a combined $1.34M — up 132% from $576K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new DMAQR positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 6 trimmed.
The largest buyer was Highbridge Capital Management, opening a new position worth an estimated $20.3K. The largest seller was Hudson Bay Capital Management, cutting an estimated $24.8K.
- 30 institutional investors held Deep Medicine Acquisition Corp. Rights (DMAQR) as of Q1 2023, up from 29 in Q4 2022.
- Funds reported $1.34M of Deep Medicine Acquisition Corp. Rights stock for Q1 2023, up 132% quarter-over-quarter.
- 4 funds opened new Deep Medicine Acquisition Corp. Rights positions in Q1 2023 and 3 closed out, a net change of +1 holder.
- The largest Deep Medicine Acquisition Corp. Rights buyer in Q1 2023 was Highbridge Capital Management, an estimated $20.3K added.
- The largest Deep Medicine Acquisition Corp. Rights seller in Q1 2023 was Hudson Bay Capital Management, an estimated $24.8K sold.
Based on aggregated 13F filings for Q1 2023.